CHS-131, a novel once daily oral treatment, decreased lesion burden of patients with relapsing-remitting course of multiple sclerosis (RRMS) in a randomized, double-blind, phase 2b, multicenter study

Authors
Category Primary study
JournalNeurology
Year 2017
This article has no abstract
Epistemonikos ID: c58dfc979e7de29941e74fa1c832a9d08f650d43
First added on: Feb 08, 2025